Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Zafirlukast is a cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50 = 0.014 μM in a cell-based calcium mobilization assay).1 It is selective for CysLT1 over CysLT2 receptors (IC50 = 58 μM). It inhibits mucus secretion induced by leukotriene D4 (LTD4; Item No. 20310) in isolated guinea pig trachea (IC50 = 0.6 μM).2 Zafirlukast (5 μM) inhibits ovalbumin-induced increases in tracheal mucus secretion in ovalbumin-sensitized guinea pigs by 65%. It inhibits LTD4-induced bronchoconstriction in anesthetized guinea pigs (ED50 = 61 nmol/kg, i.v.).3 Formulations containing zafirlukast have been used in the prophylaxis and chronic treatment of asthma.
WARNING This product is not for human or veterinary use.
1. Discovery of 3-
2. Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-
3. Pharmacological profile of MEN91507, a new CysLT1 receptor antagonist. Eur. J. Pharmacol. 451(3), 317-326 (2002).
P2Y6 signaling in alveolar macrophages prevents leukotriene-